This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bower, M. Articles by Stebbing, J. Search for Related Content PubMed PubMed Citation Articles by Bower, M. Articles by Stebbing, J. Social Bookmarking                            What's this?

Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma

From the Departments of Oncology and HIV Medicine, Chelsea and Westminster Hospital, London, United Kingdom

Address reprint requests to Mark Bower, PhD, FRCP, Department of Oncology, Chelsea and Westminster Hospital, 369 Fulham Rd, London SW10 9NH, United Kingdom; e-mail: m.bower{at}ic.ac.uk

PURPOSE: A proportion of patients with HIV infection who subsequently receive highly active antiretroviral therapy (HAART) exhibit a deterioration in their clinical status, despite control of virologic and immunologic parameters. This clinical response, known as the immune reconstitution inflammatory syndrome (IRIS), occurs secondary to an immune response against previously diagnosed pathogens.

PATIENTS AND METHODS: From our cohort of 5,832 patients treated in the HAART era, we identified 150 therapy-naive patients with a first presentation of Kaposi's sarcoma (KS). Their clinicopathologic features and progress were recorded prospectively.

RESULTS: After commencing HAART, ten patients (6.6%) developed progressive KS, which we identify as IRIS-associated KS. In a comparison of these individuals with those whose KS did not progress, we found that IRIS-KS occurred in patients with higher CD4 counts (P = .03), KS-associated edema (P = .01), and therapy with both protease inhibitors and non-nucleosides together (P = .03). Time to treatment failure was similar for both groups, although the CD4 count declined more rapidly at first, in those patients with IRIS-associated KS. Despite this initial decline, in our clinical experience HAART could be successfully continued in those with IRIS-associated KS.

CONCLUSION: We have identified IRIS-KS in a cohort of HIV patients with KS who start HAART.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J W T Elston and H Thaker Immune reconstitution inflammatory syndrome Int J STD AIDS, April 1, 2009; 20(4): 221 - 224. [Abstract] [Full Text] [PDF]

				L.-W. Qian, W. Greene, F. Ye, and S.-J. Gao Kaposi's Sarcoma-Associated Herpesvirus Disrupts Adherens Junctions and Increases Endothelial Permeability by Inducing Degradation of VE-Cadherin J. Virol., December 1, 2008; 82(23): 11902 - 11912. [Abstract] [Full Text] [PDF]

				M. C. B. Godoy, H. Rouse, J. A. Brown, P. Phillips, D. M. Forrest, and N. L. Muller Imaging Features of Pulmonary Kaposi Sarcoma Associated Immune Reconstitution Syndrome Am. J. Roentgenol., October 1, 2007; 189(4): 956 - 965. [Abstract] [Full Text] [PDF]

				R. Duprez, V. Lacoste, J. Briere, P. Couppie, C. Frances, D. Sainte-Marie, E. Kassa-Kelembho, M.-J. Lando, J.-L. Essame Oyono, B. Nkegoum, et al. Evidence for a Multiclonal Origin of Multicentric Advanced Lesions of Kaposi Sarcoma J Natl Cancer Inst, July 18, 2007; 99(14): 1086 - 1094. [Abstract] [Full Text] [PDF]

				D. T. Scadden, V. V. Muse, and R. P. Hasserjian Case records of the Massachusetts General Hospital. Case 30-2006. A 41-year-old man with dyspnea, fever, and lymphadenopathy. N. Engl. J. Med., September 28, 2006; 355(13): 1358 - 1368. [Full Text] [PDF]

				J. Stebbing, D. Mazhar, R. Lewis, C. Palmieri, E. Hatzimichael, M. Nelson, B. Gazzard, and M. Bower The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma Ann. Onc., March 1, 2006; 17(3): 503 - 506. [Abstract] [Full Text] [PDF]